

Cover Story
By Matthew Bin Han Ong
Summer of 2020 was supposed to be a brief period of respite between Wave 1 and Wave 2 of COVID-19, but out of sheer stubbornness, for reasons political, or both, SARS-CoV-2 didn't get the message.
In Brief


Clinical Roundup
Drugs & Targets
Trending Stories
- Ross Levine named chief scientific officer of Memorial Sloan Kettering Cancer Center
- Study finds no correlation between cancer burden in catchment areas and cancer centers’ CCSG funding
- How animal testing became a MAHA political wedge issue
While cancer scientists say NIH, FDA moves are premature, animal rights advocates say changes aren’t drastic enough - Under the lens: Taking a close look at the NIH and FDA declarations on animal-based research
- Latinx oncology leaders talk about the impact of federal policy on cancer outcomes in Latinx communities
- Why both somatic and germline genomic profiling are essential for precision oncology